The article reports that aminochrome, a metabolite of dopamine oxidation to neuromelanin, can be both used in a preclinical model for Parkinson's disease and also represents an endogenous neurotoxin that triggers the loss of dopaminergic neurons containing neuromelanin in the substantia nigra.